High quality stocks work long-term and also in 2020 High quality stocks work long-term and also in 2020 High quality stocks work long-term and also in 2020

High quality stocks work long-term and also in 2020

Equities 5 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Equities have reached high valuation levels, increasing the probability for negative real rate returns over a 10-year period. But with bond yields compressed everywhere investors are desperately looking for assets that can yield over the long run. High-quality stocks have done exactly that over almost four decades and in this equity update we pick out 25 high-quality stocks with long-term potential.

Our regular readers know that our view is fundamentally negative on equities. This is especially true of US equities, which have moved to levels against European equities that are historically out of proportion. There is an increasing risk that investors buying equities at current valuation levels could experience a negative real rate return over a 10-year period. But at the same time bond yields are falling and rates in the US are potentially going negative this year. What do you do as an investor?

Our general recommendation is for long-term investors to be half-exposed to the equity market and keep the remaining part of the portfolio in cash or short-term government bonds. A bit of gold would also be a good additional diversifier. The next question is then what equities investors should invest in while they wait for a setback. Long-term quality stocks have outperformed the general market since 1981 by a large margin, and in general Warren Buffett also changed his approach over time from deep value stocks to high-quality stocks with a understandable and predictable business moat. The biggest index provider in the world, MSCI Inc., uses three fundamental ratios as the components for selecting high-quality stocks: return on equity, debt-to-equity and earnings variability.

Source: Bloomberg

We prefer return on invested capital (ROIC) over return on equity as it better reflects the return on the total capital invested. Return on equity can be inflated by using a lot of debt; think financials in the years leading up to 2008. Debt-to-equity is not our preferred metric either as we would prefer net-debt-to-assets to avoid a metric with a potential negative denominator, which could happen due to a lot of share buybacks. One case is Rockwell Automation, where its debt-to-equity ratio is a mammoth 558% due to share buybacks. But if you look at its net-debt-to-assets then the ratio is only 20%, which is still high for a quality company but easily manageable through its cash flow generation. Earnings variability is a good measure unless a big shift in the competitive landscape happens, because then you will be behind the curve as a function of your lookback window to compute this earnings variability; it’s probably better just to analyse the industry outlook and apply that human judgement.

Our preferred method is to look at ROIC/WACC, where WACC is the weighted average cost of capital. If this spread is above one then the company is creating shareholder value. Secondly a good net-debt-to-assets position combined with a strong business moat in an industry with a positive outlook are the next variables we look at. Combining these variables without regard to valuation, we filter the US and European large cap segment top to 25 high-quality stocks that could do well even during a deep recession due to COVID-19. These 25 stocks have delivered on average 10% return this year in local currencies, thus outperforming the overall equity market. However, please be aware that this is not an indication of future performance.

Mkt. Cap. (USD, mn.)EV/EBITDAROIC/WACC (%)Net-debt-to-assets (%)YTD in %
Apple IncTechnologyCommunications Equipment1,395,00616.773.63-28.910.2
ASML Holding NVTechnologySemiconductor Mfg142,00537.881.24-6.213.7
Atlas Copco ABIndustrialsFlow Control Equipment48,44417.221.837.72.6
Biogen IncHealth CareBiotech49,1936.274.432.01.6
Coloplast A/SHealth CareHealth Care Supplies35,32937.866.144.232.6
Colruyt SAConsumer StaplesFood & Drug Stores8,1939.203.10-3.513.7
eBay IncConsumer DiscretionaryE-Commerce Discretionary31,76111.322.8230.826.2
Electronic Arts IncTechnologyApplication Software35,44518.582.47-40.614.2
Euronext NVFinancialsSecurity & Cmdty Exchanges6,50714.262.2920.516.7
F5 Networks IncTechnologyCommunications Equipment8,88015.581.57-39.34.4
Facebook IncCommunicationsInternet Media660,73618.102.14-33.013.0
GlaxoSmithKline PLCHealth CareLarge Pharma104,37112.272.7932.3-4.5
Knorr-Bremse AGIndustrialsRailroad Rolling Stock17,28912.733.128.65.6
Kone OyjIndustrialsComml & Res Bldg Equip & Sys35,92622.634.86-19.87.4
Lockheed Martin CorpIndustrialsDefense Primes109,07812.263.3025.81.2
Microsoft CorpTechnologyInfrastructure Software1,386,48020.172.62-16.516.6
Monster Beverage CorpConsumer StaplesBeverages38,22324.423.20-25.314.2
Neste OyjEnergyRefining & Marketing30,78710.662.67-2.016.7
NIKE IncConsumer DiscretionaryApparel, Footwear & Acc Design154,78825.053.59-5.0-1.2
Novo Nordisk A/SHealth CareLarge Pharma151,38716.678.70-8.812.7
Novozymes A/SMaterialsSpecialty Chemicals15,35519.662.6419.811.9
Roche Holding AGHealth CareLarge Pharma299,34013.693.674.59.1
Rockwell Automation IncIndustrialsMeasurement Instruments24,86416.162.7419.67.0
Unilever PLCConsumer StaplesHousehold Products139,52413.822.8035.20.7
Visa IncFinancialsConsumer Finance377,71923.682.883.43.8

Source: Bloomberg and Saxo Group

* YTD in % is the total return year-to-date in local currency


Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.